Related references
Note: Only part of the references are listed.Alemtuzumab in chronic lymphocytic leukemia: final results of a large observational multicenter study in mostly pretreated patients
M. Fiegl et al.
ANNALS OF HEMATOLOGY (2014)
Complement factor H-derived short consensus repeat 18-20 enhanced complement-dependent cytotoxicity of ofatumumab on chronic lymphocytic leukemia cells
Susanne Hoerl et al.
HAEMATOLOGICA (2013)
The mechanism of anti-CD20-mediated B cell depletion revealed by intravital imaging
Fabricio Montalvao et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Ofatumumab Is More Efficient than Rituximab in Lysing B Chronic Lymphocytic Leukemia Cells in Whole Blood and in Combination with Chemotherapy
Luca Bologna et al.
JOURNAL OF IMMUNOLOGY (2013)
Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab
Srinivas Mamidi et al.
MOLECULAR ONCOLOGY (2013)
Reduction of complement factor H binding to CLL cells improves the induction of rituximab-mediated complement-dependent cytotoxicity
S. Hoerl et al.
LEUKEMIA (2013)
Antibody Therapeutics in Cancer
Mark X. Sliwkowski et al.
SCIENCE (2013)
Boosting antibody therapy with complement
Peter Boross et al.
BLOOD (2012)
Atargeted complement-dependent strategy to improve the outcome of mAb therapy, and characterization in a murine model of metastatic cancer
Michelle Elvington et al.
BLOOD (2012)
Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy
S. Bellone et al.
BRITISH JOURNAL OF CANCER (2012)
Complement dependent cytotoxicity in chronic lymphocytic leukemia: ofatumumab enhances alemtuzumab complement dependent cytotoxicity and reveals cells resistant to activated complement
Nisar A. Baig et al.
LEUKEMIA & LYMPHOMA (2012)
Human CD59 Inhibitor Sensitizes Rituximab-Resistant Lymphoma Cells to Complement-Mediated Cytolysis
Weiguo Hu et al.
CANCER RESEARCH (2011)
rILYd4, a Human CD59 Inhibitor, Enhances Complement-Dependent Cytotoxicity of Ofatumumab against Rituximab-Resistant B-cell Lymphoma Cells and Chronic Lymphocytic Leukemia
Xiaowen Ge et al.
CLINICAL CANCER RESEARCH (2011)
Inhibition of Membrane Complement Inhibitor Expression (CD46, CD55, CD59) by siRNA Sensitizes Tumor Cells to Complement Attack In Vitro
N. Geis et al.
CURRENT CANCER DRUG TARGETS (2010)
Complement: a key system for immune surveillance and homeostasis
Daniel Ricklin et al.
NATURE IMMUNOLOGY (2010)
Monoclonal antibodies: versatile platforms for cancer immunotherapy
Louis M. Weiner et al.
NATURE REVIEWS IMMUNOLOGY (2010)
Binding of Submaximal C1q Promotes Complement-Dependent Cytotoxicity (CDC) of B Cells Opsonized with Anti-CD20 mAbs Ofatumumab (OFA) or Rituximab (RTX): Considerably Higher Levels of CDC Are Induced by OFA than by RTX
Andrew W. Pawluczkowycz et al.
JOURNAL OF IMMUNOLOGY (2009)
Cancer resistance to complement-dependent cytotoxicity (CDC): Problem-oriented research and development
Dana Gancz et al.
MOLECULAR IMMUNOLOGY (2009)
Modulation of the antitumor immune response by complement
Maciej M. Markiewski et al.
NATURE IMMUNOLOGY (2008)
Drug therapy: Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma
Bruce D. Cheson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement
Siao-Yi Wang et al.
BLOOD (2008)
Down-regulation of CD55 and CD46 expression by anti-sense phosphorothioate oligonucleotides (S-ODNs) sensitizes tumour cells to complement attack
S. Zell et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2007)
In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab
Paolo Macor et al.
CANCER RESEARCH (2007)
Mechanisms of killing by anti-CD20 monoclonal antibodies
Martin J. Glennie et al.
MOLECULAR IMMUNOLOGY (2007)
Efficient nucleofection of primary human B cells and B-CLL cells induces apoptosis, which depends on the microenvironment and on the structure of transfected nucleic acids
M. Seiffert et al.
LEUKEMIA (2007)
Complement as effector system in cancer immunotherapy
Paolo Macor et al.
IMMUNOLOGY LETTERS (2007)
RNAi therapeutics: Principles, prospects and challenges
Lars Aagaard et al.
ADVANCED DRUG DELIVERY REVIEWS (2007)
The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20
Jessica L. Teeling et al.
JOURNAL OF IMMUNOLOGY (2006)
Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines
K Takei et al.
LEUKEMIA RESEARCH (2006)
Complement function in mAb-mediated cancer immunotherapy
KA Gelderman et al.
TRENDS IN IMMUNOLOGY (2004)
Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas
JL Teeling et al.
BLOOD (2004)
Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors
Z Fishelson et al.
MOLECULAR IMMUNOLOGY (2003)
Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells
F Czauderna et al.
NUCLEIC ACIDS RESEARCH (2003)
Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study
MJ Keating et al.
BLOOD (2002)
Clinical effects of alemtuzumab (Campath-1H) in B-cell chronic lymphocytic leukemia
A Osterborg et al.
MEDICAL ONCOLOGY (2002)
Rituximab therapy of patients with B-cell chronic lymphocytic leukemia
D Huhn et al.
BLOOD (2001)
Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies
SP Treon et al.
JOURNAL OF IMMUNOTHERAPY (2001)
Advances in immunology: Complement (Second of two parts).
MJ Walport
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Advances in immunology: Complement (First of two parts).
MJ Walport
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
